`
`
` CENTER FOR DRUG EVALUATION AND
`
`
`
` RESEARCH
`
`
`
` APPLICATION NUMBER:
`
`
`
`212477Orig1s000
`
`
`
` LABELING
`
`
`
`
`
`
`
`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`
` HARVONI® safely and effectively. See full prescribing information
`
` for HARVONI.
`
`HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use
`
`
`HARVONI® (ledipasvir and sofosbuvir) oral pellets
`
`
`
`Initial U.S. Approval: 2014
`
`
`8/2019
`
`
`
`WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN
`
`
`PATIENTS COINFECTED WITH HCV AND HBV
`
`
`See full prescribing information for complete boxed warning.
`
`
`Hepatitis B virus (HBV) reactivation has been reported, in some
`cases resulting in fulminant hepatitis, hepatic failure, and death.
`
`(5.1)
`
`------------------------------RECENT MAJOR CHANGES ----------------------
`
`8/2019
`Indications and Usage (1)
`
`
`Dosage and Administration
` Recommended Treatment Regimen and Duration in
` Patients 3 Years of Age and Older with Genotype 1, 4, 5,
`
` or 6 HCV (2.2)
`
` Recommended Dosage in Pediatric Patients 3 Years of
` Age and Older (2.4)
` 8/2019
`
` Preparation and Administration of Oral Pellets (2.5)
`8/2019
`
`
`-------------------------------INDICATIONS AND USAGE------------------------
`HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus
`(HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog
`NS5B polymerase inhibitor, and is indicated for the treatment of
`chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years
`
`of age and older:
` Genotype 1, 4, 5, or 6 infection without cirrhosis or with
`
`compensated cirrhosis
` Genotype 1 infection with decompensated cirrhosis, in combination
`
`with ribavirin
`
` Genotype 1 or 4 infection who are liver transplant recipients
`
`
`without cirrhosis or with compensated cirrhosis, in combination with
`
`r bavirin. (1)
`
`------------------------DOSAGE AND ADMINISTRATION----------------------
` Testing prior to the initiation of therapy: Test all patients for HBV
`
`infection by measuring HBsAg and anti-HBc. (2.1)
`
`
` Recommended treatment regimen and duration in patients 3 years
`
`of age and older: (2.2)
`
`
`
`
`
`
`HCV
`Genotype
`
`Patient Population
`
`
`
`Treatment-naïve without
`cirrhosis or with compensated
`
`cirrhosis (Child-Pugh A)
`Treatment-experienced without
`cirrhosis
`Treatment-experienced with
`compensated cirrhosis (Child-
`Pugh A)
`
`Treatment-naïve and treatment-
`experienced with
`
`decompensated cirrhosis (Child-
`Pugh B or C)
`
`Treatment-naïve and treatment-
`experienced liver transplant
`recipients without cirrhosis, or
`with compensated cirrhosis
`(Child-Pugh A)
`
`Treatment-naïve and treatment-
`experienced without cirrhosis or
`with compensated cirrhosis
`(Child-Pugh A)
`
`
`Genotype
`1
`
`Genotype
`1 or 4
`
`
`Genotype
`4, 5, or 6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Regimen
`and
`Duration
`
`HARVONI
`12 weeks
`
`HARVONI
`12 weeks
`HARVONI
`
`24 weeks
`
`HARVONI
`
`+ ribavirin
`12 weeks
`
`HARVONI
`
`+ ribavirin
`12 weeks
`
`HARVONI
`
`12 weeks
`
`
`
`
`
`Reference ID: 4483725
`
`
`
` Recommended dosage in adults: One tablet (90 mg of ledipasvir
`
`and 400 mg of sofosbuvir) taken orally once daily with or without
`
`
`food. (2.3)
`
` Recommended dosage in pediatric patients 3 years and older:
`
`Recommended dosage of HARVONI in pediatric patients 3 years of
`age and older is based on weight. Refer to Table 2 of the full
`prescribing information for specific dosing guidelines based on body
`weight. (2.4)
` HCV/HIV-1 coinfection: For adult and pediatric patients with
`
`HCV/HIV-1 coinfection, follow the dosage recommendations in the
`tables in the full prescribing information. (2.3, 2.4)
`
` If used in combination with ribavirin, follow the recommendations for
`
`
`r bavirin dosing and dosage modifications. (2.3, 2.4)
`
` A dosage recommendation cannot be made for patients with severe
`
`
`renal impairment or end stage renal disease. (2.6)
`
`
`
`-----------------------DOSAGE FORMS AND STRENGTHS-------------------
` Tablets: 90 mg of ledipasvir and 400 mg of sofosbuvir; 45 mg of
`
`ledipasvir and 200 mg of sofosbuvir. (3)
`
` Oral Pellets: 45 mg of ledipasvir and 200 mg of sofosbuvir; 33.75 mg
`
`of ledipasvir and 150 mg of sofosbuvir. (3)
`
`
`
`
`
`
`
`--------------------------------CONTRAINDICATIONS-----------------------------
`If used in combination with ribavirin, all contraindications to ribavirin
`also apply to HARVONI combination therapy. (4)
`
`
`-------------------------WARNINGS AND PRECAUTIONS---------------------
` Risk of Hepatitis B Virus Reactivation: Test all patients for evidence
`
`of current or prior HBV infection before initiation of HCV treatment.
`Monitor HCV/HBV coinfected patients for HBV reactivation and
`hepatitis flare during HCV treatment and post-treatment follow-up.
`Initiate appropriate patient management for HBV infection as
`clinically indicated. (5.1)
` Bradycardia with amiodarone coadministration: Serious symptomatic
`
`bradycardia may occur in patients taking amiodarone, particularly in
`patients also receiving beta blockers, or those with underlying
`cardiac comorbidities and/or advanced liver disease.
`Coadministration of amiodarone with HARVONI is not
`recommended. In patients without alternative, viable treatment
`options, cardiac monitoring is recommended. (5.2, 6.2, 7.2)
`
`
`
`
`
`-------------------------------ADVERSE REACTIONS----------------------------
` The most common adverse reactions (incidence greater than or
`
`equal to 10%, all grades) observed with treatment with HARVONI
`were fatigue, headache, and asthenia. (6.1)
`
`
`
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact Gilead
`
`Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or
`
`www.fda.gov/medwatch.
`
`---------------------------------DRUG INTERACTIONS---------------------------
` Coadministration with amiodarone may result in serious
`
`symptomatic bradycardia. Use of HARVONI with amiodarone is not
`
`recommended. (5.2, 6.2, 7.2)
`
` P-gp inducers (e.g., rifampin, St. John’s wort): May alter
`
`concentrations of ledipasvir and sofosbuvir. Use of HARVONI with
`P-gp inducers is not recommended. (5.3, 7, 12.3)
`
` Frequent monitoring of international normalized ratio (INR) values is
`
`recommended in patients receiving warfarin. (7.1)
`
` Consult the full prescribing information prior to use for potential drug
`
`
`interactions. (5.2, 5.3, 7, 12.3)
`
`
`See 17 for PATIENT COUNSELING INFORMATION and
`FDA-approved patient labeling.
`
`
`
`
`
`
`
`Revised: 08/2019
`
`
`
`
`
`
`
`
`
`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`
`WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN
`
` PATIENTS COINFECTED WITH HCV AND HBV
`
` 1 INDICATIONS AND USAGE
` 2 DOSAGE AND ADMINISTRATION
`
`
`2.1 Testing Prior to the Initiation of Therapy
`
`
`2.2 Recommended Treatment Regimen and Duration in
`
`Patients 3 Years of Age and Older with Genotype 1, 4, 5, or
`
`
` 6 HCV
`
`2.3 Recommended Dosage in Adults
`
`2.4 Recommended Dosage in Pediatric Patients 3 Years of
`
`
`Age and Older
`
`2.5 Preparation and Administration of Oral Pellets
`
`2.6 Severe Renal Impairment and End Stage Renal Disease
`
`
` 3 DOSAGE FORMS AND STRENGTHS
`
` 4 CONTRAINDICATIONS
` 5 WARNINGS AND PRECAUTIONS
`
`
`5.1 Risk of Hepatitis B Virus Reactivation in Patients
`
`
` Coinfected with HCV and HBV
`
`5.2 Serious Symptomatic Bradycardia When Coadministered
`
`
` with Amiodarone
`
`5.3 Risk of Reduced Therapeutic Effect Due to Use with P-gp
`
`Inducers
`
`5.4 Risks Associated with Ribavirin Combination Treatment
`
`
`
` 6 ADVERSE REACTIONS
`6.1 Clinical Trials Experience
`
`
`6.2
` Postmarketing Experience
`
`
`
` 7 DRUG INTERACTIONS
`
` 7.1 Potential for Drug Interaction
`
`
`
`7.2 Established and Potentially Significant Drug Interactions
`
`
`
`
`
`
`7.3
`
`
`
`
`
`
`
`
`
`
`
` Drugs without Clinically Significant Interactions with
`
`
` HARVONI
`
`8 USE IN SPECIFIC POPULATIONS
`
`8.1
` Pregnancy
`8.2
` Lactation
`8.3 Females and Males of Reproductive Potential
`
`8.4
` Pediatric Use
`
`8.5
` Geriatric Use
`
` Renal Impairment
`8.6
`8.7
` Hepatic Impairment
`
` 10 OVERDOSAGE
`11 DESCRIPTION
` 12 CLINICAL PHARMACOLOGY
`
`
`12.1 Mechanism of Action
`
`12.2 Pharmacodynamics
`12.3 Pharmacokinetics
`12.4 Microbiology
`13 NONCLINICAL TOXICOLOGY
`
`
`
` 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`14 CLINICAL STUDIES
`
`14.1 Description of Clinical Trials
`
`
` 14.2 Clinical Trials in Subjects with Genotype 1 HCV
`
`
`
`14.3 Clinical Trials in Subjects with Genotype 4, 5, or 6 HCV
`
`
` 14.4 Clinical Trials in Subjects Coinfected with HCV and HIV-1
`
`
`
`14.5 Clinical Trials in Liver Transplant Recipients and/or Subjects with
`
`
` Decompensated Cirrhosis
`
`14.6 Clinical Trial in Pediatric Subjects
`
`
`
` 16 HOW SUPPLIED/STORAGE AND HANDLING
`17 PATIENT COUNSELING INFORMATION
`
`* Sections or subsections omitted from the full prescribing information are not
`listed.
`
`
`
`
`
`
`
`Reference ID: 4483725
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`FULL PRESCRIBING INFORMATION
`
`WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS
`
`
`COINFECTED WITH HCV AND HBV
`
`
`
`
`Test all patients for evidence of current or prior hepatitis B virus (HBV) infection
`before initiating treatment with HARVONI. HBV reactivation has been reported in
`HCV/HBV coinfected patients who were undergoing or had completed treatment
`with HCV direct acting antivirals and were not receiving HBV antiviral therapy.
`
`Some cases have resulted in fulminant hepatitis, hepatic failure, and death.
`Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation
`during HCV treatment and post-treatment follow-up. Initiate appropriate patient
`management for HBV infection as clinically indicated [see Warnings and
`
`Precautions (5.1)].
`
`1
`INDICATIONS AND USAGE
`
`
`HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age
`and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and
`2.3) and Clinical Studies (14)]:
` genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
`
`
` genotype 1 infection with decompensated cirrhosis, for use in combination with
`
`ribavirin
` genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or
`
`with compensated cirrhosis, for use in combination with ribavirin
`
`DOSAGE AND ADMINISTRATION
`2
`Testing Prior to the Initiation of Therapy
`2.1
`Test all patients for evidence of current or prior HBV infection by measuring hepatitis B
`surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV
`treatment with HARVONI [see Warnings and Precautions (5.1)].
`2.2 Recommended Treatment Regimen and Duration in Patients 3 Years of Age
`and Older with Genotype 1, 4, 5, or 6 HCV
`Table 1 shows the recommended HARVONI treatment regimen and duration based on
`patient population. Relapse rates are affected by baseline host and viral factors and
`differ between treatment durations for certain subgroups [see Clinical Studies (14)].
`For patients with HCV/HIV-1 coinfection, follow the dosage recommendations in Table 1
`[see Clinical Studies (14)]. Refer to Drug Interactions (7) for dosage recommendations
`for concomitant HIV-1 antiviral drugs.
`
`
`
`
`
`Reference ID: 4483725
`
`
`
`Table 1
`
`
`
` HCV Genotype
`
` Recommended Treatment Regimen and Duration for HARVONI in
`
`Patients 3 Years of Age and Older with Genotype 1, 4, 5, or 6 HCV
`
`
` Patient Population
` Treatment Regimen and Duration
`
`
`Treatment-naïve without cirrhosis or with
`compensated cirrhosis (Child-Pugh A)
`
`
`
`HARVONI 12 weeksa
`
`Treatment-experiencedb without cirrhosis
`
`HARVONI 12 weeks
`
`HARVONI 24 weeksc
`
`
`HARVONI + ribavirind 12 weeks
`
`HARVONI + ribavirind 12 weeks
`
`
`
` HARVONI 12 weeks
`
`Treatment-experiencedb with compensated
`cirrhosis (Child-Pugh A)
`Treatment-naïve and treatment
`experiencedb with decompensated
`
`cirrhosis (Child-Pugh B or C)
`Treatment-naïve and treatment
`experiencedb liver transplant recipients
`without cirrhosis, or with compensated
`cirrhosis (Child-Pugh A)
`Treatment-naïve and treatment-
`experiencedb, without cirrhosis or with
`
` compensated cirrhosis (Child-Pugh A)
`a. HARVONI for 8 weeks can be considered in treatment-naïve genotype 1 patients without cirrhosis
`
` who have pretreatment HCV RNA less than 6 million IU/mL [see Clinical Studies (14.2)].
` b. Treatment-experienced adult and pediatric subjects have failed a peginterferon alfa +/- ribavirin based
`
`
` regimen with or without an HCV protease inhibitor.
` c. HARVONI + ribavirin for 12 weeks can be considered in treatment-experienced genotype 1 patients
`
`with cirrhosis who are eligible for ribavirin [see Dosage and Administration (2.3 and 2.4) and Clinical
`Studies (14.2)].
`
`d. See Dosage and Administration 2.3 and 2.4 for ribavirin dosage recommendations.
`
`2.3 Recommended Dosage in Adults
`The recommended dosage of HARVONI in adults with genotype 1, 4, 5, or 6 HCV is
`one tablet (90 mg ledipasvir and 400 mg sofosbuvir) taken orally once daily with or
`without food [see Clinical Pharmacology (12.3)].
`The daily dosage of ribavirin is weight-based (1000 mg for patients <75 kg and 1200 mg
`for those ≥75 kg) administered orally in two divided doses with food.
`In patients with decompensated cirrhosis, the starting dosage of ribavirin is 600 mg and
`can be titrated up to 1000 mg for patients <75 kg and 1200 mg for those ≥75 kg in two
`divided doses with food. If the starting dosage of ribavirin is not well tolerated, the
`
`dosage should be reduced as clinically indicated based on hemoglobin levels.
`For further information on ribavirin dosing and dosage modifications, refer to the
`ribavirin prescribing information [see Clinical Studies (14.5)].
`
`2.4 Recommended Dosage in Pediatric Patients 3 Years of Age and Older
`The recommended dosage of HARVONI in pediatric patients 3 years of age and older
`with genotype 1, 4, 5, or 6 HCV using HARVONI tablets or oral pellets is based on
`weight (Table 2). Table 3 provides the weight-based dosage of ribavirin when used in
`
`
`Genotype 1
`
`
`Genotype 1 or 4
`
`
`Genotype 4, 5, or 6
`
`
`
`Reference ID: 4483725
`
`
`
`combination with HARVONI for pediatric patients. Take HARVONI tablets or pellets
`(with or without food) once daily [see Dosage and Administration (2.5), Clinical
`Pharmacology (12.3), and Clinical Studies (14.6)]. HARVONI pellets can be taken in
`pediatric patients who cannot swallow the tablet formulation.
`
`Table 2
`
`Dosing for Pediatric Patients 3 Years and Older Using HARVONI
`Tablets or Oral Pellets
`
`Body Weight
`
`(kg)
`
`
`at least 35
`
`
`Dosing of HARVONI Tablets or Oral Pellets
`one 90 mg/400 mg tablet once daily
`
`or
`
`
`two 45 mg/200 mg tablets once daily
`or
`
`two 45 mg/200 mg packets of pellets once daily
`one 45 mg/200 mg tablet once daily
`or
`one 45 mg/200 mg packet of pellets once daily
`
`one 33.75 mg/150 mg packet of pellets once daily
`
`HARVONI Daily Dose
`
`
`90 mg/400 mg per day
`
`
`45 mg/200 mg per day
`
`
`33.75 mg/150 mg per day
`
`
`
`17 to less than
`
`35
`
`
`less than17
`
`
`
`Table 3
`
` Recommended Dosing for Ribavirin in Combination Therapy with
`HARVONI for Pediatric Patients 3 Years and Older
`
` Body Weight (kg)
`Oral Ribavirin Daily Dosagea
`
` 15 mg per kg per day
`(divided dose AM and PM)
`600 mg per day
`(1 x 200 mg AM, 2 x 200 mg PM)
`800 mg per day
`(2 x 200 mg AM, 2 x 200 mg PM)
`1000 mg per day
`(2 x 200 mg AM, 3 x 200 mg PM)
`1200 mg per day
`(3 x 200 mg AM, 3 x 200 mg PM)
`
` a. The daily dosage of ribavirin is weight-based and is administered orally in two divided doses with food.
`
`
`
`
`
` less than 47
`
`47–49
`
`50–65
`
`66–80
`
`
`greater than 80
`
`
`
`
`
`
`
`Reference ID: 4483725
`
`
`
` 2.5 Preparation and Administration of Oral Pellets
`
`Do not chew HARVONI pellets. If HARVONI pellets are administered with food, sprinkle
`the pellets on one or more spoonfuls of non-acidic soft food at or below room
`temperature. Examples of non-acidic foods include pudding, chocolate syrup, mashed
`potato, and ice cream. Take HARVONI pellets within 30 minutes of gently mixing with
`food and swallow the entire contents without chewing to avoid a bitter aftertaste.
`2.6 Severe Renal Impairment and End Stage Renal Disease
`No dosage recommendation can be given for patients with severe renal impairment
`(estimated Glomerular Filtration Rate [eGFR] less than 30 mL/min/1.73 m2) or with end
`stage renal disease (ESRD) due to higher exposures (up to 20-fold) of the predominant
`sofosbuvir metabolite [see Use in Specific Populations (8.6) and Clinical Pharmacology
`(12.3)].
`
`3
`DOSAGE FORMS AND STRENGTHS
`
`HARVONI is available as tablets or pellets for oral use. Each dosage form is available in
`two dose strengths.
` 90 mg/400 mg Tablets: orange, diamond-shaped, film-coated tablet debossed
`
`with “GSI” on one side and “7985” on the other side of the tablet. Each tablet
`
`contains 90 mg ledipasvir and 400 mg sofosbuvir.
` 45 mg/200 mg Tablets: white, capsule-shaped, film-coated tablets, debossed
`
`with “GSI” on one side and “HRV” on the other side. Each tablet contains 45 mg
`
`ledipasvir and 200 mg sofosbuvir.
` 45 mg/200 mg Pellets: orange pellets in unit-dose packets. Each packet contains
`
`45 mg ledipasvir and 200 mg sofosbuvir.
` 33.75 mg/150 mg Pellets: orange pellets in unit-dose packets. Each packet
`
`contains 33.75 mg ledipasvir and 150 mg sofosbuvir.
`
`4
` CONTRAINDICATIONS
`
`If HARVONI is administered with ribavirin, the contraindications to ribavirin also apply to
`this combination regimen. Refer to the ribavirin prescribing information for a list of
`contraindications for ribavirin [see Dosage and Administration (2.2)].
`
`5
`WARNINGS AND PRECAUTIONS
`
`5.1 Risk of Hepatitis B Virus Reactivation in Patients Coinfected with HCV and
`HBV
`
`Hepatitis B virus (HBV) reactivation has been reported in HCV/HBV coinfected patients
`who were undergoing or had completed treatment with HCV direct acting antivirals, and
`who were not receiving HBV antiviral therapy. Some cases have resulted in fulminant
`hepatitis, hepatic failure, and death. Cases have been reported in patients who are
`HBsAg positive and also in patients with serologic evidence of resolved HBV infection
`(i.e., HBsAg negative and anti-HBc positive). HBV reactivation has also been reported
`in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk
`
`
`
`Reference ID: 4483725
`
`
`
`of HBV reactivation associated with treatment with HCV direct-acting antivirals may be
`increased in these patients.
`HBV reactivation is characterized as an abrupt increase in HBV replication manifesting
`as a rapid increase in serum HBV DNA level. In patients with resolved HBV infection,
`reappearance of HBsAg can occur. Reactivation of HBV replication may be
`accompanied by hepatitis, i.e., increases in aminotransferase levels and, in severe
`cases, increases in bilirubin levels, liver failure, and death can occur.
`Test all patients for evidence of current or prior HBV infection by measuring HBsAg and
`anti-HBc before initiating HCV treatment with HARVONI. In patients with serologic
`evidence of HBV infection, monitor for clinical and laboratory signs of hepatitis flare or
`HBV reactivation during HCV treatment with HARVONI and during post-treatment
`follow-up. Initiate appropriate patient management for HBV infection as clinically
`indicated.
`5.2 Serious Symptomatic Bradycardia When Coadministered with Amiodarone
`Postmarketing cases of symptomatic bradycardia, as well as fatal cardiac arrest and
`cases requiring pacemaker intervention, have been reported when amiodarone is
`coadministered with HARVONI. Bradycardia has generally occurred within hours to
`days, but cases have been observed up to 2 weeks after initiating HCV treatment.
`Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or
`advanced liver disease, may be at increased risk for symptomatic bradycardia with
`coadministration of amiodarone. Bradycardia generally resolved after discontinuation of
`HCV treatment. The mechanism for this effect is unknown.
`Coadministration of amiodarone with HARVONI is not recommended. For patients
`taking amiodarone who have no other alternative, viable treatment options and who will
`be coadministered HARVONI:
` Counsel patients about the risk of serious symptomatic bradycardia
`
` Cardiac monitoring in an in-patient setting for the first 48 hours of
`
`coadministration is recommended, after which outpatient or self-monitoring of the
`heart rate should occur on a daily basis through at least the first 2 weeks of
`treatment.
`
`Patients who are taking HARVONI who need to start amiodarone therapy due to no
`other alternative, viable treatment options should undergo similar cardiac monitoring as
`outlined above.
`Due to amiodarone’s long half-life, patients discontinuing amiodarone just prior to
`starting HARVONI should also undergo similar cardiac monitoring as outlined above.
`Patients who develop signs or symptoms of bradycardia should seek medical evaluation
`immediately. Symptoms may include near-fainting or fainting, dizziness or
`lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest
`pains, confusion or memory problems [see Adverse Reactions (6.2), Drug Interactions
`(7.2)].
`
`
`
`Reference ID: 4483725
`
`
`
`5.3 Risk of Reduced Therapeutic Effect Due to Use with P-gp Inducers
`The concomitant use of HARVONI and P-gp inducers (e.g., rifampin, St. John’s wort)
`may significantly decrease ledipasvir and sofosbuvir plasma concentrations and may
`lead to a reduced therapeutic effect of HARVONI. Therefore, the use of HARVONI with
`P-gp inducers (e.g., rifampin or St. John’s wort) is not recommended [see Drug
`Interactions (7.2)].
`5.4 Risks Associated with Ribavirin Combination Treatment
`If HARVONI is administered with ribavirin, the warnings and precautions for ribavirin, in
`particular the pregnancy avoidance warning, apply to this combination regimen. Refer to
`the ribavirin prescribing information for a full list of the warnings and precautions for
`ribavirin [see Dosage and Administration (2.2)].
`
`
`6
`ADVERSE REACTIONS
`
`
`The following serious adverse reactions are described below and elsewhere in labeling:
`
` Serious Symptomatic Bradycardia When Coadministered with Amiodarone [see
`
`
`Warnings and Precautions (5.2)].
`6.1 Clinical Trials Experience
`Because clinical trials are conducted under widely varying conditions, adverse reaction
`rates observed in the clinical trials of a drug cannot be directly compared to rates in the
`clinical trials of another drug and may not reflect the rates observed in practice.
`If HARVONI is administered with ribavirin to adults, refer to the prescribing information
`for ribavirin for a description of ribavirin-associated adverse reactions.
`Clinical Trials in Adult Subjects
`The safety assessment of HARVONI was based on pooled data from three randomized,
`open-label Phase 3 clinical trials (ION-3, ION-1, and ION-2) of subjects with genotype 1
`HCV with compensated liver disease (with and without cirrhosis) including 215, 539,
`and 326 subjects who received HARVONI once daily by mouth for 8, 12 and 24 weeks,
`respectively [see Clinical Studies (14)].
`
`The proportion of subjects who permanently discontinued treatment due to adverse
`events was 0%, less than 1%, and 1% for subjects receiving HARVONI for 8, 12, and
`24 weeks, respectively.
`The most common adverse reactions (at least 10%) were fatigue and headache in
`subjects treated with 8, 12, or 24 weeks of HARVONI.
`Table 3 lists adverse reactions (adverse events assessed as causally related by the
`investigator, all grades) observed in at least 5% of subjects receiving 8, 12, or 24 weeks
`treatment with HARVONI in clinical trials. The majority of adverse reactions presented in
`
`Table 4 occurred at severity of grade 1. The side-by-side tabulation is to simplify
`presentation; direct comparison across trials should not be made due to differing trial
`designs.
`
`
`
`
`Reference ID: 4483725
`
`
`
`
`
`Table 4
`
`Adverse Reactions (All Grades) Reported in ≥5% of Subjects
`Receiving 8, 12, or 24 Weeks of Treatment with HARVONI
`HARVONI
`HARVONI
`HARVONI
`24 weeks
`12 weeks
`8 weeks
`
`
`
`(N=326)
`
`(N=539)
`
`(N=215)
`
`16%
`13%
`18%
`Fatigue
`
`11%
`14%
`17%
`Headache
`
`6%
`7%
`9%
`Nausea
`
`
`4%
`3%
`7%
`Diarrhea
`
`3%
`5%
`6%
`Insomnia
`The safety assessment of HARVONI was also based on pooled data from three open-
`label trials (Study 1119, ION-4, and ELECTRON-2) in 118 subjects with chronic HCV
`genotype 4, 5, or 6 infection with compensated liver disease (with or without cirrhosis)
`[see Clinical Studies (14.3)]. The subjects received HARVONI once daily by mouth for
`12 weeks. The safety profile in subjects with chronic HCV genotype 4, 5, or 6 infection
`with compensated liver disease was similar to that observed in subjects with chronic
`HCV genotype 1 infection with compensated liver disease. The most common adverse
`reactions occurring in at least 10% of subjects were asthenia (18%), headache (14%),
`and fatigue (10%).
`Adverse Reactions in Subjects with Cirrhosis
`The safety assessment of HARVONI with or without ribavirin was based on a
`randomized, double-blind and placebo-controlled trial in treatment-experienced
`genotype 1 subjects with compensated cirrhosis and was compared to placebo in the
`SIRIUS trial. Subjects were randomized to receive 24 weeks of HARVONI once daily by
`mouth without ribavirin or 12 weeks of placebo followed by 12 weeks of HARVONI once
`daily by mouth + ribavirin [see Clinical Studies (14.2)]. Table 5 presents the adverse
`reactions, as defined above, that occurred with at least 5% greater frequency in
`subjects treated with 24 weeks of HARVONI or 12 weeks of HARVONI + ribavirin,
`compared to those reported for 12 weeks of placebo. The majority of the adverse
`reactions presented in Table 5 were Grade 1 or 2 in severity.
`
`
`
`
`Reference ID: 4483725
`
`
`
`Adverse Reactions with ≥5% Greater Frequency Reported in
`Treatment-Experienced Subjects with Cirrhosis Receiving HARVONI
`for 24 Weeks or HARVONI + RBV for 12 Weeks Compared to Placebo
`for 12 weeks
`
`Table 5
`
`
`
`
`
`Reference ID: 4483725
`
` Placebo
`
`12 weeks
`
` (N=77)
`23%
`16%
`1%
`1%
`0
`1%
`1%
`0
`
` HARVONI + RBV
`
`12 weeks
`
` (N=76)
`36%
`13%
`4%
`11%
`4%
`9%
`7%
`1%
`
`HARVONI
`24 weeks
`
` (N=78)
`31%
`Asthenia
`29%
`Headache
`18%
`Fatigue
`5%
`Cough
`9%
`Myalgia
`3%
`Dyspnea
`8%
`Irritability
`5%
`Dizziness
`Adverse Reactions in Subjects Coinfected with HIV-1
`The safety assessment of HARVONI was based on an open-label clinical trial in
`335 genotype 1 or 4 subjects with HCV/HIV-1 coinfection who were on stable
`antiretroviral therapy in Study ION-4 [see Clinical Studies (14.4)]. The safety profile in
`HCV/HIV-1 coinfected subjects was similar to that observed in HCV mono-infected
`subjects. The most common adverse reactions occurring in at least 10% of subjects
`were headache (20%) and fatigue (17%).
`Adverse Reactions in Liver Transplant Recipients and/or Subjects with Decompensated
`
`Cirrhosis
`The safety assessment of HARVONI with ribavirin (RBV) in liver transplant recipients
`and/or those who had decompensated liver disease was based on pooled data from two
`Phase 2 open-label clinical trials including 336 subjects who received HARVONI plus
`RBV for 12 weeks. Subjects with Child-Pugh-Turcotte (CPT) scores greater than 12
`were excluded from the trials [see Clinical Studies (14.5)].
`The adverse events observed were consistent with the expected clinical sequelae of
`liver transplantation and/or decompensated liver disease, or the known safety profile of
`HARVONI and/or ribavirin.
`Decreases in hemoglobin to less than 10 g/dL and 8.5 g/dL during treatment were
`observed in 38% and 13% of subjects treated with HARVONI plus RBV for 12 weeks,
`respectively. Ribavirin was permanently discontinued in 11% of subjects treated with
`HARVONI plus RBV for 12 weeks.
`Liver Transplant Recipients with Compensated Liver Disease:
`Among the 174 liver transplant recipients with compensated liver disease who received
`HARVONI with RBV for 12 weeks, 2 (1%) subjects permanently discontinued HARVONI
`due to an adverse event.
`
`
`
`
`Subjects with Decompensated Liver Disease:
`Among the 162 subjects with decompensated liver disease (pre- or post-transplant) who
`received HARVONI with RBV for 12 weeks, 7 (4%) subjects died, 4 (2%) subjects
`underwent liver transplantation, and 1 subject (<1%) underwent liver transplantation and
`died during treatment or within 30 days after discontinuation of treatment. Because
`these events occurred in patients with advanced liver disease who are at risk of
`progression of liver disease including liver failure and death, it is not possible to reliably
`assess the contribution of drug effect to outcomes. A total of 4 (2%) subjects
`permanently discontinued HARVONI due to an adverse event.
`Less Common Adverse Reactions Reported in Clinical Trials (less than 5%): The
`following adverse reactions occurred in less than 5% of subjects receiving HARVONI in
`any one trial. These events have been included because of their seriousness or
`assessment of potential causal relationship.
`
`Psychiatric disorders: depression (including in subjects with pre-existing history of
`psychiatric illness).
`Depression (particularly in subjects with pre-existing history of psychiatric illness)
`occurred in subjects receiving sofosbuvir containing regimens. Suicidal ideation and
`suicide have occurred in less than 1% of subjects treated with sofosbuvir in
`combination with ribavirin or pegylated interferon/ribavirin in other clinical trials.
`Laboratory Abnormalities
`Bilirubin Elevations: Bilirubin elevations of greater than 1.5xULN were observed in
`3%, less than 1%, and 2% of subjects treated with HARVONI for 8, 12, and
`24 weeks, respectively. Bilirubin elevations of greater than 1.5xULN were observed
`in 3%, 11%, and 3% of subjects with compensated cirrhosis treated with placebo,
`HARVONI + ribavirin for 12 weeks and HARVONI for 24 weeks, respectively, in the
`SIRIUS trial.
`Lipase Elevations: Transient, asymptomatic lipase elevations of greater than 3xULN
`were observed in less than 1%, 2%, and 3% of subjects treated with HARVONI for 8,
`12, and 24 weeks, respectively. Transient, asymptomatic lipase elevations of greater
`than 3x ULN were observed in 1%, 3%, and 9% of subjects with compensated
`cirrhosis treated with placebo, HARVONI + ribavirin for 12 weeks, and HARVONI for
`24 weeks, respectively, in the SIRIUS trial.
`Creatine Kinase: Creatine kinase was not assessed in Phase 3 trials ION-3, ION-1,
`or ION-2 of HARVONI. Creatine kinase was assessed in the ION-4 trial. Isolated,
`asymptomatic creatine kinase elevations of greater than or equal to 10xULN was
`observed in 1% of subjects treated with HARVONI for 12 weeks in the ION-4 trial
`and has also been previously reported in subjects treated with sofosbuvir in
`combination with ribavirin or peginterferon/ribavirin in other clinical trials.
`Adverse Reactions in Pediatric Subjects 3 Years of Age and Older
`The safety assessment of HARVONI in pediatric subjects 3 years of age and older is
`based on data from a Phase 2, open-label clinical trial (Study 1116). In total, 226
`subjects were enrolled, which included 223 subjects without cirrhosis or with
`
`
`
`Reference ID: 4483725
`
`
`
`compensated cirrhosis who were treated with HARVONI for 12 weeks; one genotype 1
`treatment-experienced subject with cirrhosis who was treated with HARVONI for 24
`weeks; and two genotype 3 subjects who were treated with HARVONI + ribavirin for 24
`weeks. The adverse reactions observed were consistent with those observed in clinical
`studies of HARVONI in adults. Limited safety data are available in pediatric subjects
`receiving HARVONI for 24 weeks. No Grade 3 or 4 adverse reactions or discontinuation
`due to an adverse reaction was observed in those pediatric subjects receiving
`HARVONI for 24 weeks [see Clinical Studies (14.6)].
`6.2 Postmarketing Experience
`The following adverse reactions have been identified during post approval use of
`HARVONI. Because postmarketing reactions are reported voluntarily from a population
`of uncertain size, it is not always possibl